Israeli wound administration firm RedDress at present introduced the completion of a $26 million Collection D financing spherical with participation from ATHOS Biopharma GmbH, and different life science traders together with Buyers Group of HCS Capital and the Ragnar Crossover Fund. The newest funding spherical brings the overall quantity raised by RedDress to $43 million.
RedDress has developed a personalised and autologous wound administration resolution created from sufferers personal blood. The brand new funds can be used to advertise elevated adoption of the corporate’s product, institution of worldwide partnerships, and develop RedDress’ proprietary blood-based expertise to deal with extra situations.
RedDress has pioneered a proprietary blood-based expertise to deal with continual wounds that has nearly zero threat of rejection and is much less expensive. Its ActiGraft product household is an autologous, point-of-care wound administration resolution that creates, in real-time, an in-vitro blood clot from sufferers’ personal entire blood. As soon as utilized to the wound, the blood clot jump-starts the wound therapeutic course of, serves as a protecting overlaying, and optimizes the physique’s personal therapeutic potential. The ActiGraft product household can be utilized for all kinds of continual wounds together with diabetic and neuropathic ulcers, venous ulcers, strain accidents, traumatic wounds, post-surgical wounds, pores and skin tears, surgical wounds and extra.
RedDress cfounder and CEO Alon Kushnir mentioned, « Therapeutic is in our blood, and we’re grateful for the continued assist from our traders as we advance our mission of supplying healthcare suppliers with an efficient resolution to deal with continual and sophisticated wounds by way of an progressive system that harnesses the ability of affected person’s personal blood. This newest funding spherical additional validates the efficacy and powerful market efficiency of the ActiGraft system and gives us with crucial assets to develop our autologous, blood-based wound care options so we are able to proceed to develop new improvements in different healthcare fields. »
Since RedDress acquired FDA clearance and a CE Mark in 2020, ActiGraft has helped over 6,000 sufferers within the US and 30 different international locations.
Printed by Globes, Israel enterprise information – en.globes.co.il – on Could 24, 2023.
© Copyright of Globes Writer Itonut (1983) Ltd., 2023.